Jonathan C. Javitt

CIK: 0001303782

Transaction Breakdown

Open Market Buys (P)1 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

NRXP

NRX Pharmaceuticals, Inc.

DirectorOfficer10% Owner

Discretionary Trading P&L

Holdings

Transaction History (2 total)

NRXP
NRX Pharmaceuticals, Inc.
Apr 9, 2025
Award(A)
Stock Option (right to buy)
Direct
125K shares-
NRXP
NRX Pharmaceuticals, Inc.
Dec 17, 2024
Purchase(P)
Direct
40K shares at avg. $1.17$47K

		Type	Shares	Price		Ownership
Apr 9, 2025	NRXP NRX Pharmaceuticals, Inc.	Award(A) Stock Option (right to buy)	125,000	-	-	Direct
Dec 17, 2024	NRXP NRX Pharmaceuticals, Inc.	Purchase(P)	40,000	$1.17	$46,800	Direct

1-2 of 2 transactions

About Javitt Jonathan C

Javitt Jonathan C (SEC CIK 0001303782) files insider reports with the SEC as Chairman and Chief Scientist of NRX Pharmaceuticals, Inc. (NRXP).

Signal8 holds 2 ownership filings by Javitt Jonathan C, all Form 4s, filed between Dec 18, 2024 and Sep 10, 2025. Those filings report 2 transactions, from Dec 17, 2024 to Apr 9, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Javitt Jonathan C's filings is in WILMINGTON, DE.

Recent filings by Javitt Jonathan C

Apr 9, 2025: Grant or award of NRXP derivative securities (Form 4, code A).
Dec 17, 2024: Open-market purchase of NRXP shares (Form 4, code P).

Other insiders filing for NRX Pharmaceuticals, Inc. (NRXP)

Casper Joseph Michael, Chief Operating Officer
McBride Dennis, Director
Hurvitz Chaim, Director
Flynn Patrick John, Director
B Group, Inc., 10% Owner
ABRAMS MICHAEL S, Chief Financial Officer

How to read Form 4 transaction codes